CRIS Current Research Information System

BON, ISABELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.938
EU - Europa 2.546
AS - Asia 2.494
AF - Africa 248
SA - Sud America 186
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 9.423
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.907
SG - Singapore 852
CN - Cina 678
GB - Regno Unito 559
VN - Vietnam 447
SE - Svezia 443
IT - Italia 423
DE - Germania 335
HK - Hong Kong 237
BR - Brasile 147
IN - India 137
RU - Federazione Russa 135
IE - Irlanda 122
FR - Francia 118
TG - Togo 110
UA - Ucraina 96
NL - Olanda 94
ZA - Sudafrica 53
EE - Estonia 45
JO - Giordania 36
NG - Nigeria 35
FI - Finlandia 34
BG - Bulgaria 33
CI - Costa d'Avorio 29
BE - Belgio 23
JP - Giappone 22
CH - Svizzera 19
ID - Indonesia 19
AR - Argentina 17
AT - Austria 15
BD - Bangladesh 15
CA - Canada 15
PL - Polonia 15
MX - Messico 11
SC - Seychelles 10
ES - Italia 9
IR - Iran 9
PT - Portogallo 7
TR - Turchia 7
KR - Corea 6
AU - Australia 5
CL - Cile 5
EC - Ecuador 5
LB - Libano 4
PE - Perù 4
RO - Romania 4
UZ - Uzbekistan 4
CO - Colombia 3
CZ - Repubblica Ceca 3
EU - Europa 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
DK - Danimarca 2
EG - Egitto 2
GR - Grecia 2
IL - Israele 2
MA - Marocco 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
SA - Arabia Saudita 2
SI - Slovenia 2
TH - Thailandia 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
AQ - Antartide 1
AZ - Azerbaigian 1
BH - Bahrain 1
BJ - Benin 1
BS - Bahamas 1
DZ - Algeria 1
ET - Etiopia 1
GI - Gibilterra 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IQ - Iraq 1
KE - Kenya 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LV - Lettonia 1
MD - Moldavia 1
MS - Montserrat 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
RS - Serbia 1
RW - Ruanda 1
SN - Senegal 1
TN - Tunisia 1
Totale 9.423
Salva come PNG Salva come JPEG
Città #
Singapore 568
Southend 484
Ashburn 463
Fairfield 395
Chandler 337
Hong Kong 234
Santa Clara 221
Woodbridge 209
Seattle 190
Wilmington 170
Houston 166
Ann Arbor 164
Dong Ket 148
Princeton 138
Cambridge 133
Dublin 122
Beijing 119
Lomé 110
Bologna 96
Boardman 95
Ho Chi Minh City 88
Hanoi 85
Florence 72
Nanjing 59
Westminster 54
Jacksonville 52
Padova 49
Berlin 45
Turin 39
Los Angeles 37
Amman 36
Abeokuta 33
Sofia 33
Munich 32
Redondo Beach 31
Jinan 30
Abidjan 29
New York 29
Shenyang 29
San Diego 27
Buffalo 26
Redmond 26
Saint Petersburg 24
Brussels 23
Hefei 23
Milan 23
Hebei 22
Tokyo 20
Dallas 19
Helsinki 19
Tianjin 18
Phoenix 17
Zhengzhou 17
Chicago 16
Dearborn 16
Bremen 15
Nanchang 15
Rome 15
São Paulo 15
Des Moines 14
Ningbo 14
Jiaxing 13
Olalla 13
Bern 12
Changsha 12
Falls Church 12
Guangzhou 12
Jakarta 12
Nuremberg 12
Atlanta 11
Falkenstein 11
Frankfurt am Main 11
Hangzhou 11
London 11
Turku 11
Mülheim 10
Shanghai 10
Taizhou 10
Bühl 9
Haikou 9
Warsaw 9
Yubileyny 9
Haiphong 8
Stockholm 8
Toronto 8
Wuhan 8
Brooklyn 7
Da Nang 7
Ha Long 7
Lanzhou 7
Paris 7
San Francisco 7
Taiyuan 7
Fuzhou 6
Mahé 6
Quận Một 6
Rio de Janeiro 6
Seoul 6
Thái Bình 6
Vienna 6
Totale 6.201
Salva come PNG Salva come JPEG
Nome #
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia 233
Restriction Factors expression decreases in HIV-1 patients after cART 233
Acute onset myopericarditis as unusual presentation of primary HIV infection 220
Analysis of the effects of HIV-1 Tat on the survival and differentiation of vessel wall-derived mesenchymal stem cells 214
Discordant resistance interpretations in multi-treated HIV-1 patients 212
Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naive HIV-1 patients with acute and chronic infection 211
Comparison of the Aptima HIV-1 Quant Dx Assay with the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 Test for HIV-1 Viral Load Quantification in Plasma Samples from HIV-1-Infected Patients. 206
Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1 197
HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients. 179
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 177
Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19 174
Encephalopathy in COVID-19 Presenting With Acute Aphasia Mimicking Stroke 170
M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures 169
Effects of Antiretroviral Molecules on Survival and Gene Expression of an Osteoblast-like Cell Line 168
Antiretroviral molecules and cardiovascular diseases. 164
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 163
Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. 162
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 159
Recent and long-lasting infections: the need for avidity testing in HIV-1 infected subjects. 157
Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. 156
Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy. 153
Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. 149
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 149
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz 149
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 148
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 146
HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity 145
HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy 144
HIV-1 subtype C transmission network: The phylogenetic reconstruction strongly supports the epidemiological data. 144
HIV-related mechanisms in atherosclerosis and cardiovascular diseases. 143
HIV and kidney: A dangerous liaison 143
Human T-lymphotropic virus type 1 (HTLV-1) prevalence and quantitative detection of DNA proviral load in individuals with indeterminate/positive serological results 142
HIV-1 infection of a nurse from a newborn with an unknown HIV infection: a case report. 142
Low avidity antibody: a reliable method to diagnose a recent HIV-1 infection. 141
Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns 139
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 139
Durable viral suppression in an HIV-infected patient in the absence of antiretroviral therapy 134
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 134
Prevalence of antiretroviral drug resistance in untreated persons newly diagnosed with HIV-1 infection 132
Reversal of major genotypic tipranavir mutations under long-term treatment with tipranavir/ritonavir itself with very limited optimized background, during deep salvage antiretroviral therapy 130
V3 net charge: additional tool in HIV-1 tropism prediction 130
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 130
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 126
An HIV type 2 case series in Italy: A phylogenetic analysis 123
Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. 122
HIV-1 gp120 impairs the differentiation and survival of cord blood CD34+ HPCs induced to the erythroid lineage. 122
Do the HIV-1 subtypes circulating in Italy resemble the Red Queen running in Carroll's novel? 120
null 113
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy 111
Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. 111
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: Results from the DIVA study group 110
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. 110
Fulminant type 1 autoimmune hepatitis in a recently diagnosed celiac disease patient. 109
Significant association between statin-associated myalgia and Vitamin D deficiency among treated HIV-infected patients 108
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study) 108
Improving counterfactual reasoning with kernelised dynamic mixing models 105
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group. 101
Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy 101
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy 98
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir 97
HBsAg seroreversion in HBsAg-negative/HBcAb-positive patients with HIV infection treated with direct-acting antivirals for HCV: A retrospective study 93
COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection. 90
Hepatitis A virus in a medical setting in Madagascar: a lesson for public health 84
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients 78
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome. 75
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir 70
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine. 68
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir 67
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir. 65
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir 50
Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain. 48
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. 33
Totale 9.646
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.464
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.464
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021519 0 0 0 0 0 56 7 36 111 44 37 228
2021/20221.375 71 75 66 147 103 62 31 107 57 230 252 174
2022/20231.577 142 231 59 193 138 96 38 100 271 57 171 81
2023/2024404 25 66 39 52 31 81 19 24 9 29 21 8
2024/20251.602 72 247 133 129 295 90 73 40 19 129 55 320
2025/20261.740 335 320 260 250 391 184 0 0 0 0 0 0
Totale 9.646